{"id":"placebo-for-enlicitide","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect, natural disease progression, or regression to the mean. Placebos are essential for blinded trial designs to isolate the true therapeutic benefit of the investigational drug.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:23.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for Enlicitide"}]},"trialDetails":[{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":"Hyperlipidemia","enrollment":975},{"nctId":"NCT07058077","phase":"PHASE2, PHASE3","title":"A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-21","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":153},{"nctId":"NCT05952869","phase":"PHASE3","title":"A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-08","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":303},{"nctId":"NCT05952856","phase":"PHASE3","title":"A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-10","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":2912},{"nctId":"NCT06814106","phase":"PHASE1","title":"A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-06","conditions":"Healthy","enrollment":37},{"nctId":"NCT05261126","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-10","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":381},{"nctId":"NCT06655311","phase":"PHASE1","title":"A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-30","conditions":"Healthy, Hypercholesterolemia","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Enlicitide","genericName":"Placebo for Enlicitide","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for Enlicitide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}